https://www.selleckchem.com/pr....oducts/PCI-24781.htm
01) and a clinical net benefit in the range of probabilities between 50 and 90% for the prediction of PCa (Fig.1). In the prediction of high-grade PCa, the RC presented good discrimination (AUC=0.79), good calibration (p=0.48) and a clinical net benefit in the range of probabilities between 20 and 80% (Fig.1). The Rotterdam prostate cancer risk App accurately predicts the risk of PCa and particularly high-grade cancer. The clinical net benefit is wide for high-grade cancer and therefore its implementation in clinical practice should b
Like
Comment
Share
